Sigachi Industries Limited, a prominent name in the pharmaceutical excipients, APIs, and specialty ingredients sector, is set to elevate its research and development capabilities with the inauguration of a new R&D center in Hyderabad. This center will play a pivotal role in advancing the company’s innovation strategy, focusing on the complete API development cycle, from laboratory innovations to commercialization and global regulatory submissions.
The establishment of this state-of-the-art R&D center underscores Sigachi’s commitment to enhancing its scientific and technical resources. The facility is strategically designed to support the development of key APIs, with a specific emphasis on regulatory approvals and Certificate of Suitability (CEP) filings across critical therapeutic areas. A selection of key molecules has already been earmarked for accelerated development as part of the company’s robust pipeline.
The new center will be staffed by a dedicated team of 32–35 skilled scientists who will focus on advancing product development for international markets. With a strong emphasis on quality-by-design (QbD) and regulatory readiness, this center is set to become a cornerstone in Sigachi’s pharmaceutical innovation efforts, ensuring that the company stays at the forefront of industry trends.
Amit Raj Sinha, Managing Director and CEO of Sigachi Industries, commented, “By integrating R&D capabilities and consolidating API development and analytical functions under one roof, we are strengthening our backward integration. This investment not only enhances our R&D capabilities but also sets the stage for Sigachi to become a globally competitive supplier in regulated pharmaceutical markets.”
Sigachi Industries has a long history in the pharmaceutical industry, known for its advancements in APIs, intermediates, excipients, and vitamin-mineral blends. The company operates five manufacturing facilities across Telangana, Gujarat, and Karnataka, with plans to further extend its global presence. Sigachi has established subsidiaries in the UAE and the USA to improve its proximity to clients and offer quicker responses to market demands.
The company’s core ethos revolves around customer-centricity, regulatory compliance, and continuous innovation. With a focus on leveraging cutting-edge technology and global expertise, Sigachi aims to develop high-quality pharma, food, and nutrition solutions that significantly improve healthcare outcomes.
Sigachi’s commitment to excellence is reflected in its continuous investment in research and development, ensuring that the products meet the highest standards of quality and safety. With over 36 years of industry experience, Sigachi has built a reputation as a trusted partner for pharmaceutical and nutraceutical companies in over 65 countries.
By collaborating with healthcare partners, regulatory agencies, and global stakeholders, Sigachi is committed to expanding access to reliable, high-quality pharmaceutical ingredients. The new R&D facility in Hyderabad marks an important step in the company’s ongoing efforts to meet the growing demand for innovative, high-quality solutions in the pharmaceutical sector.
